Abstract
COVID-19 has led to morbidity in millions of patients, ranging from mild flu-like symptoms to severe respiratory failure, necessitating oxygen supplementation and mechanical ventilation, and ultimately death. The SARS-CoV-2 virus reacts with angiotensin-converting enzyme 2 (ACE2) molecules that are especially found in alveolar epithelial type 2 cells in the lungs and thereby causes a loss in lung surfactant, a protein-lipid mixture that is crucial for both native immunity and reduction of surface tension in the lung alveoli. Lung surfactant insufficiency results in atelectasis and loss of functional lung tissue amid an inflammatory storm and may be countered by treating COVID-19 pneumonia patients with exogenous lung surfactant, preferably by aerosol delivery of a novel dry powder synthetic lung surfactant. More research on timing, dosing, and delivery of synthetic lung surfactant in patients with COVID-19 pneumonia is of crucial importance to implement this approach in clinical practice.
Keywords: lung surfactant, alveolar type 2 cells, respiratory failure, SARS-CoV-2, COVID-19, pneumonia.
Coronaviruses
Title:Synthetic Lung Surfactant Treatment for COVID-19 Pneumonia
Volume: 2 Issue: 1
Author(s): Frans J. Walther*Alan J. Waring
Affiliation:
- Departments of Pediatrics and Internal Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA & The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California,United States
Keywords: lung surfactant, alveolar type 2 cells, respiratory failure, SARS-CoV-2, COVID-19, pneumonia.
Abstract: COVID-19 has led to morbidity in millions of patients, ranging from mild flu-like symptoms to severe respiratory failure, necessitating oxygen supplementation and mechanical ventilation, and ultimately death. The SARS-CoV-2 virus reacts with angiotensin-converting enzyme 2 (ACE2) molecules that are especially found in alveolar epithelial type 2 cells in the lungs and thereby causes a loss in lung surfactant, a protein-lipid mixture that is crucial for both native immunity and reduction of surface tension in the lung alveoli. Lung surfactant insufficiency results in atelectasis and loss of functional lung tissue amid an inflammatory storm and may be countered by treating COVID-19 pneumonia patients with exogenous lung surfactant, preferably by aerosol delivery of a novel dry powder synthetic lung surfactant. More research on timing, dosing, and delivery of synthetic lung surfactant in patients with COVID-19 pneumonia is of crucial importance to implement this approach in clinical practice.
Export Options
About this article
Cite this article as:
Walther J. Frans *, Waring J. Alan , Synthetic Lung Surfactant Treatment for COVID-19 Pneumonia, Coronaviruses 2021; 2 (1) : e160223186890 . https://dx.doi.org/10.2174/2666796701999201014160428
DOI https://dx.doi.org/10.2174/2666796701999201014160428 |
Print ISSN 2666-7967 |
Publisher Name Bentham Science Publisher |
Online ISSN 2666-7975 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inodilators in the Management of Low Cardiac Output Syndrome After Pediatric Cardiac Surgery
Current Vascular Pharmacology The Clinical Pharmacology of Short Acting Analgo-Sedatives in Neonates
Current Clinical Pharmacology Past, Present and Future Drugs for the Treatment of Obsessive- Compulsive Disorder
Current Medicinal Chemistry Multimodality Imaging in Acute Ischemic Stroke
Current Medical Imaging Targeting Tumors Using Estrogen Receptor Ligand Conjugates
Current Cancer Drug Targets Pharmacogenetics of Colon Cancer and Potential Implications for 5- Fluorouracil-Based Chemotherapy
Current Pharmacogenomics Lipid-Lowering Drugs Acting at the Level of the Gastrointestinal Tract
Current Pharmaceutical Design Anesthetic Cardioprotection in Clinical Practice From Proof-of-Concept to Clinical Applications
Current Pharmaceutical Design The Clinical Significance of Indocyanine Green Excretion Test in Evaluation of Liver Functional Reserve
Current Signal Transduction Therapy The Therapeutic Potential of Neural Stem Cells in Cerebral Ischemia
Current Signal Transduction Therapy Nummular Eczema: An Updated Review
Recent Patents on Inflammation & Allergy Drug Discovery Optimisation of Synthetic Vector Systems for Cancer Gene Therapy – The Role of the Excess of Cationic Dendrimer Under Physiological Conditions
Current Topics in Medicinal Chemistry Device Therapies: New Indications and Future Directions
Current Cardiology Reviews Refractory Angina Pectoris: Lessons from the Past and Current Perspectives
Current Pharmaceutical Design Central Nervous System Manifestations in Systemic Lupus Erythematosus
Current Rheumatology Reviews New Therapies for Sepsis
Current Topics in Medicinal Chemistry Renoprotection with Anti-Hypertensives: Reduction of Proteinuria and Improvement of Oxygenation via Inhibition of the Renin-Angiotensin System
Current Hypertension Reviews Diagnosis and Treatment of Unilateral Forms of Primary Aldosteronism
Current Hypertension Reviews From Brain Ischemia-Reperfusion Injury to Possible Sporadic Alzheimers Disease
Current Neurovascular Research Nitric Oxide is a Central Common Metabolite in Vascular Dysfunction Associated with Diseases of Human Pregnancy
Current Vascular Pharmacology